Rotavirus vaccine - International Medica Foundation
Alternative Names: Rhesus reassortant tetravalent rotavirus vaccine - NIAID; Rhesus rotavirus vaccine reassortant - International Medica Foundation; Rotamune; RotaShield; Rotavirus - NIAID; Rotavirus vaccine rhesus reassortant tetravalent - NIAID; RRV-TVLatest Information Update: 25 Sep 2021
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer International Medica Foundation; Shanghai BravoBio Co
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rotavirus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rotavirus-infections(In neonates, Prevention) in China (PO)
- 21 Jul 2015 Rotavirus vaccine is still in phase-II development for rotavirus infections
- 09 Oct 2014 Rotavirus vaccine licensed to BravoVax worldwide, excluding USA, Europe and Japan, for the prevention of Rotavirus infections